Pharmacology-AI platform simplifies data analysis
REPROCELL Introduces Pharmacology-AI, a New Service Simplifying Data Analysis in Drug Development Studies
REPROCELL has recently launched a groundbreaking commercial service called Pharmacology-AI, following the successful completion of an EXCELERATE project in collaboration with the Hartree National Centre for Digital Innovation (HNCDI), a partnership between the Science and Technology Facilities Council (STFC) Hartree Centre and IBM. This project has resulted in the development of a machine learning (ML) platform that streamlines and expedites the analysis of large datasets from drug development studies.
The innovative Pharmacology-AI platform will assist researchers at REPROCELL in identifying the key inter-individual differences that significantly impact drug response and related clinical outcomes. Traditional analysis of such extensive datasets can be time-consuming and requires substantial expertise, but Pharmacology-AI simplifies the process. This service aims to enable pharmaceutical companies to design more successful and cost-effective clinical trials by identifying patient populations that are most likely to benefit from new drugs at an earlier stage in the drug development process. Furthermore, the software can shed light on the reasons behind varying responses to commonly prescribed drugs, distinguishing those who derive little or no benefit from those who do.
''Pharmacology-AI is unique in its ability to quickly reveal the genomic or clinical features driving drug response,” said Graeme Macluskie, Director of Precision Medicine at REPROCELL. “We’re excited to see what insights the platform can offer to clients developing early-stage precision medicine strategies.”
According to Peter Waggett, IBM's Director of Research, processing clinical and drug response data using machine learning poses challenges due to its complex nature. In collaboration with REPROCELL, IBM and STFC have closely collaborated to develop the Pharmacology-AI platform. This platform leverages explainable AI techniques to provide human experts with valuable insights from pharmacological data. Waggett expresses satisfaction in fulfilling their commitment to support UK organizations through the HNCDI program, utilizing advanced AI technology to accelerate scientific discoveries.
Professor Kate Royse, Director of STFC Hartree Centre, emphasizes that this project exemplifies the potential of artificial intelligence in creating long-term societal and economic impact. She highlights that the advantages of machine learning extend beyond the technology sector and have the potential to benefit various industries across the UK.
Comments